You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors

    SBC: NEONC TECHNOLOGIES INC            Topic: BT

    DESCRIPTION provided by applicant Glioblastoma multiforme GBM the most common and malignant of all gliomas has a median survival time of months Standard of care chemotherapy using temozolomide TMZ is effective initially but the GBM inevitably recurs and these recurrent tumors are resistant to TMZ There are currently no effective treatment options for patients with TMZ resistant ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Testing Smad7-based biologics for treating chronic wounds

    SBC: Taiga Biotechnologies, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Chronic skin wounds associated with various diseases (e.g., diabetes) and aberrant healing from acute wounding (e.g., hypertrophic scarring) is a major health care burden, which need scientific discovery-based therapeutic interventions. Our previous studies show that Smad7, a TGFb signaling antagonist, accelerates skin wound healing. We have developed a Smad7 f ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Testing the effects of a selective calpain-2 inhibitor on spontaneous recurrent seizures in mouse models of epilepsy

    SBC: NEURAEGIS INC            Topic: 103

    AbstractEpilepsy is the most prevalent neurological diseases after migraines. Current antiepileptic drug treatments mainly attempt to reduce excitation or enhance inhibition in order to control seizures. Unfortunately, such therapeutics result in a number of undesirable side-effects, and demonstrate limited efficacy against drug- resistant cases of epilepsy. So far, no treatment has been developed ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Testing the feasibility of Rendever with older adults with cognitive impairments and their adult children.

    SBC: RENDEVER, INC.            Topic: NIA

    Alzheimer s disease affects approximatelymillion AmericansNIAand bythis number is expected to more than double tomillionUntil cures for the dementias are discoverednew technologies are imperative that can help reduce the emotional burden of AD ADRD for older adults and their care giversGoal C of NIA s strategic planIn this STTRSmall Business Technology TransferPhase I studywe test the feasibility ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Test of Elliptical Accommodative Intra-Ocular Lens

    SBC: SHENASA MEDICAL            Topic: N/A

    DESCRIPTION: The overall research objective is demonstration of acceptance in living animals, and of optical performance in primate eyes , of an elliptical accommodative intra-ocular lens (EAIOL). Thisis a patented technology. The lens is designed for implantation in a human eye after cataract e ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  6. TESTS OF ATTENTION AND MEMORY IN INDIVIDUALS WITH INTELLECTUAL LIMITATIONS

    SBC: PRAXIS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Clinicians and investigators alike rely on tests of attention and memory in a host of fields -- among them psychology, neurology, psychiatry, pediatrics, gerontology, and epidemiology. Yet one segment of the population has been passed by in these assessment efforts: individuals who have limited verbal communication abilities, a group that includes persons with ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  7. TESTS OF ATTENTION AND MEMORY IN INDIVIDUALS WITH INTELLECTUAL LIMITATIONS

    SBC: PRAXIS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Clinicians and investigators alike rely on tests of attention and memory in a host of fields--among them psychology, neurology, psychiatry, pediatrics, gerontology, and epidemiology. Yet 1 segment of the population has been passed by in these assessment efforts: individuals who have limited verbal communication abilities, a group that includes persons with ment ...

    STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  8. The Allogeneic Heart Stem Cell Trial in Hypoplastic Left Heart Syndrome Patients

    SBC: CAPRICOR, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant One of the most complex forms of congenital heart disease hypoplastic left heart syndrome HLHS affects an average of in every newborns with a mortality rate of up to percent during the first year of life The overall goal f our research is to develop safe and effective ways to improve short term and long term survival rates in babies born with HL ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. The Antibody Registry: A Community Authority for Antibody Research Resource Identifiers

    SBC: SCICRUNCH            Topic: 300

    Project SummaryOne of the most glaring yet easily addressable gaps in our current scientific workflow and publication system is improving the way that methods are reportedin particularthe lack of key methodological details necessary for interpreting and reproducing a studyMost authors continue to cite the name of the reagentlike an antibody using the vendorand the city where the vendor is locatedb ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors

    SBC: SIXONE SOLUTIONS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government